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Arteriolar remodeling in 
essential hypertension: are 
connective tissue growth factor 
and transforming growth factor 
involved?
B Rodriguez-Iturbe1
Gómez-Garre et al. report increased expression of connective tissue 
growth factor and transforming growth factor-β and worsening of 
remodeling in subcutaneous arterioles of patients with essential 
hypertension during amlodipine treatment. Losartan improves 
remodeling without changes in cytokine expression. The discordant 
effects of two well-accepted treatments for hypertension underline 
the need for further studies on therapy-induced changes in arteriolar 
remodeling.
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Hypertension is responsible for 7 mil-
lion premature deaths yearly and 4.5% 
of the disease burden worldwide (64 
million disability-adjusted life years).1 
Patients with essential hypertension have 
structural alterations of the precapillary 
arterioles that result from incompletely 
understood mechanisms triggered by 
baro-mechanical stress and impaired 
endothelial function. Th ese structural 
alterations are responsible, at least in 
part, for the increased peripheral resist-
ance in this condition and are due to a 
combination of two processes: hyper-
trophic remodeling (encroachment of 
thickened media on the arteriolar lumen) 
and eutrophic remodeling (reduction 
of external diameter and lumen while 
the cross-sectional area of the media is 
unchanged). In both types, the media–
lumen (M:L) ratio of the resistance arteri-
oles (<350 µm in diameter) is increased. 
Eutrophic remodeling, representing a 
rearrangement of the same amount of 
tissue around a smaller lumen, is pre-
dominant in spontaneously hypertensive 
rats and in humans with mild essential 
hypertension. Th is process results from a 
complex interplay of extracellular matrix 
components and adhesion molecules, 
apoptosis, and profi brotic and proinfl am-
matory cytokines (reviewed by Intengan 
and Schiff rin2). Th e renin–angiotensin 
system plays a pivotal role in the arte-
riolar remodeling, and previous studies 
have shown that angiotensin receptor 
type 1 (AT1) blockers
3 and angiotensin-
converting enzyme inhibitors4 reduce the 
M:L ratio to a similar degree aft er 1 year 
of treatment.
In this issue, Gómez-Garre et al.5 
evaluate remodeling that focuses on the 
expression of cytokines in arterioles in 
gluteal subcutaneous biopsies of patients 
with essential hypertension. Th ey report 
that hypertensive patients had increased 
expression of connective tissue growth 
factor (CTGF), transforming growth fac-
tor-β (TGFβ), and collagens III and IV. 
In addition, they found that aft er 1 year 
of treatment, losartan prevented the 
increment of CTGF, TGFβ, and collagen 
III expression observed in amlodipine-
treated patients with similar degrees of 
blood pressure control.
Th e investigation of local expression of 
cytokines and the evaluation of treatment 
with AT1 receptor blockers are a logi-
cal consequence of the recognition that 
angio tensin II is a true cytokine that reg-
ulates cell growth and increases the pro-
duction of extracellular matrix through 
its AT1 receptors. Angiotensin II-induced 
profi brotic actions are mediated by both 
TGFβ and CTGF,6,7 and it is a reasonable 
assumption that improvement of arteri-
olar remodeling by angiotensin receptor 
blockade should be associated with the 
suppression of these cytokines.
Th e fi ndings of Gómez-Garre et al.5 
confi rm that losartan improves arteriolar 
lesions (that is, reduces the M:L ratio); 
however, this is accomplished with-
out signifi cant reduction of TGFβ and 
CTGF expression. Amlodipine, in con-
trast, increases the expression of these 
cytokines and worsens remodeling (that 
is, increases the M:L ratio). Th erefore, the 
study fi ndings may be interpreted as sup-
porting the preferential use of AT1 recep-
tor blockers in the treatment of essential 
hypertension. However, certain caveats 
must be taken into account. Th e arteri-
olar morphometry in this study was done 
in paraffi  n-embedded biopsies, rather 
than in preparations of dissected arteri-
oles mounted in an isometric myograph. 
As the authors recognize, the diff erence 
in technique was probably responsible 
for the fact that the external and internal 
(lumen) diameters and the medial cross-
sectional area that they report5 were two 
to three times smaller than previously 
reported values in resistance arterioles 
obtained from subcutaneous gluteal 
biopsies.3,4 Similarly, the baseline M:L 
ratios in the present studies were about 
eight times higher than those obtained 
with vessels mounted on a pressurized 
myograph. Furthermore, the media 
width and media cross-sectional area in 
the amlodipine-treated group were sig-
nifi cantly reduced with therapy, despite 
an increment in the M:L ratio; this indi-
cates that the low lumen diameter (the 
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parameter more easily aff ected by the 
avoidance of myograph-assisted tech-
nique) was the determining factor in the 
increased M:L ratio values.
Nevertheless, the reduction observed 
in the M:L ratio was about 15%, reason-
ably close to the reduction of about 20% 
observed in other studies.3 Unfortu-
nately, the baseline (before-treatment) 
M:L ratio was significantly higher in 
the losartan-treated group than in the 
amlodipine-treated group (see Table 2 
in Gómez-Garre et al.5), and although 
it may be argued that the differences 
between losartan and amlodipine are 
even more remarkable because the 
former was applied to patients with more 
severe cases, comparison of the eff ects of 
two treatments on a given variable is dif-
fi cult when the starting characteristics of 
the variable are not similar.
As noted by the authors5, CTGF, 
TGFβ, and collagen IV expressions 
were not reduced by losartan treatment; 
rather, this drug prevented the increase 
observed with amlodipine treatment. 
Interestingly, the expression of collagen 
III was reduced by both treatment sched-
ules.
The villain role of amlodipine is, at 
least to me, somewhat unexpected, as in 
vitro studies have shown that amlodipine 
inhibits proliferation of vascular smooth 
muscle cells,8 downregulates expression 
of collagens, and increases collagenase 
type IV activity.9 Inasmuch as the sponta-
neous evolution of cytokine expression in 
the resistance arterioles of patients with 
well-controlled mild essential hyperten-
sion is unknown (it would be unethical 
to withhold antihypertensive treatment 
for 1 year), the conclusion that losartan 
prevented, or that amlodipine caused, an 
increment in cytokine expression is open 
to question. Nevertheless, this important 
study discloses discordant eff ects of two 
well-accepted treatments of essential 
hypertension on the structural changes 
of resistance arterioles. Taken together 
with previously reported investigations 
and recent clinical studies,10 these results 
would speak in favor of the use of AT1 
receptor blockers in this condition and 
underline the need of further studies 
to defi ne the eff ects of antihypertensive 
drugs on arterial remodeling.
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ACE inhibition and glomerular 
repair: restructuring or 
regeneration?
JA Joles1, B Braam1 and MC Verhaar2
In this issue of Kidney International, Andrea Remuzzi et al. convincingly 
demonstrate glomerular repair in spontaneous renal disease by ACE 
inhibition. These findings provoke questions about how ACE inhibition 
(or AT1R blockade) can on the one hand actually repair some diseased 
kidneys while on the other interfering with normal renal development 
or the recovery of other diseased kidneys.
Kidney International (2006) 69, 1105–1107. doi:10.1038/sj.ki.5000237
Suppression of angiotensin formation 
by angiotensin-converting enzyme 
(ACE) inhibitors or blockade of the 
angiotensin II receptor type 1 (AT1R) 
can induce regression of injury in 
patients with non-diabetic or diabetic 
proteinuric nephropathy.1 Regression 
of glomerular injury by ACE inhibition 
or AT1R blockade has also been shown 
in rodents, both in spontaneous mod-
els of renal disease such as in aging and 
in the Munich Wistar Frömter (MWF) 
rat,2 and in diverse experimental models 
including puromycin aminonucl eoside 
nephropathy, chronic nitric oxide 
synthase inhibition, and five-sixths 
nephrectomy.3 In this issue, Dr. Andrea 
Remuzzi and his colleagues go one step 
further and convincingly demonstrate 
glomerular repair.4
Remuzzi et al. found that the extent 
of glomerular damage in MWF rats at 
60 weeks of age, aft er 10 weeks of ACE 
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